Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,618.00-0.20%ETH$2,695.89-0.68%GOLD$4,191.90+0.84%OIL$89.82+0.44%
Smart Investors Daily
SID Premium
PH

NASDAQ · PHVS

Pharvaris N.V.

Healthcare · Biotechnology

$30.49

Up+$0.43 (+1.40%)

Updated Oct 6, 2026, 7:29 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.56B
P/E ratio
-6.64
Dividend yield
0.00%
52-week range
$24.95 – $43.25
Volume
816.23K
Avg. volume
336.54K

Price performance · PHVS

PHVS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

PHVS closed at $30.49 after 20 trading sessions, down 19.42% for the selected period.

Last close
$30.49
Period change
-19.42%
Period low
$30.49
Period high
$38.86
Daily close
View OHLC price history
PHVS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$31.19$31.47$30.15$30.49816.23K
Oct 2, 2026$31.21$31.55$30.69$31.19591.39K
Oct 1, 2026$31.74$31.98$30.90$31.01654.35K
Sep 30, 2026$31.84$32.05$31.14$31.72839.84K
Sep 29, 2026$31.93$32.34$31.23$31.73459.29K
Sep 28, 2026$32.00$32.46$31.39$31.91753.33K
Sep 25, 2026$33.08$33.615$31.96$32.02597.65K
Sep 24, 2026$32.88$33.84$31.91$32.99949K
Sep 23, 2026$35.19$35.3082$32.87$33.07654.29K
Sep 22, 2026$35.82$36.27$34.90$35.20588.6K
Sep 21, 2026$36.33$36.88$35.50$36.02653.74K
Sep 18, 2026$38.09$38.20$36.075$36.37580.26K
Sep 17, 2026$37.81$38.93$37.595$38.001.14M
Sep 16, 2026$38.12$38.38$37.0003$37.55829K
Sep 15, 2026$39.12$40.00$37.75$38.061.75M
Sep 14, 2026$38.16$40.46$38.10$38.86998K
Sep 11, 2026$38.125$40.60$37.47$38.021.45M
Sep 10, 2026$37.60$39.03$37.00$37.511.32M
Sep 9, 2026$38.26$39.18$37.05$37.741.43M
Sep 8, 2026$40.96$43.25$37.60$37.846.33M

Latest PHVS news

The latest Smart Investors Daily articles mentioning PHVS.

Stock researchCompany · Overview

PHVS research

Overview

Company profile and research snapshot.

Company profile

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$45.60
Implied upside
—
Analysts
—
PHVS recent ratings
DateFirmRatingTarget
Sep 10, 2026GuggenheimBuy—
Sep 9, 2026Leerink PartnersOutperform—
Sep 9, 2026Morgan StanleyOverweight—
Sep 9, 2026Wells FargoOverweight—
Sep 9, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 19, 2026

What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?

Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary and secondary endpoints with statistical significance, supporting deucrictibant XR as a potential prophylactic treatment option. Management plans to use CHAPTER-3 data in upcoming marketing authorization applications for deucrictibant XR in hereditary angioedema. The statistically significant CHAPTER-3 outcome...

Yahoo · Sep 10, 2026

Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?

Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a 95% confidence interval of 72% to 90% and a p-value below 0.0001. The global, double-blind study randomized 85 participants to […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By